These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36559080)

  • 1. In Situ Co-Amorphization of Olanzapine in the Matrix and on the Coat of Pellets.
    da Costa NF; Azevedo RF; Lopes JA; Fernandes AI; Pinto JF
    Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulfonic Acid Derivatives in the Production of Stable Co-Amorphous Systems for Solubility Enhancement.
    da Costa NF; Santos IA; Fernandes AI; Pinto JF
    J Pharm Sci; 2022 Dec; 111(12):3327-3339. PubMed ID: 36007560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization.
    da Costa NF; Daniels R; Fernandes AI; Pinto JF
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solventless amorphization and pelletization using a high shear granulator. Part II; Preparation of co-amorphous mixture-layered pellets using indomethacin and arginine.
    Kondo K; Rades T
    Eur J Pharm Biopharm; 2022 Dec; 181():183-194. PubMed ID: 36400253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
    Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
    J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tannic acid as a co-former in co-amorphous systems: Enhancing their physical stability, solubility and dissolution behavior.
    Fael H; Demirel AL
    Int J Pharm; 2020 May; 581():119284. PubMed ID: 32243965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (Co-)amorphization of enantiomers - Investigation of the amorphization process, the physical stability and the dissolution behavior.
    Holzapfel K; Liu J; Rades T; Leopold CS
    Int J Pharm; 2022 Mar; 616():121552. PubMed ID: 35131351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downstream Processing of Amorphous and Co-Amorphous Olanzapine Powder Blends.
    da Costa NF; Daniels R; Fernandes AI; Pinto JF
    Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 35893791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential application of low molecular weight excipients for amorphization and dissolution enhancement of carvedilol.
    Pešić N; Dapčević A; Ivković B; Kachrimanis K; Mitrić M; Ibrić S; Medarević D
    Int J Pharm; 2021 Oct; 608():121033. PubMed ID: 34419592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-amorphization of atorvastatin by lisinopril as a co-former for solubility improvement.
    Li W; Song J; Li J; Li M; Tian B; He Z; Liu X; Fu Q
    Int J Pharm; 2021 Sep; 607():120971. PubMed ID: 34363915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solid state properties and drug release behavior of co-amorphous indomethacin-arginine tablets coated with Kollicoat® Protect.
    Petry I; Löbmann K; Grohganz H; Rades T; Leopold CS
    Eur J Pharm Biopharm; 2017 Oct; 119():150-160. PubMed ID: 28602869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
    Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
    Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved Dissolution Properties of Co-amorphous Probucol with Atorvastatin Calcium Trihydrate Prepared by Spray-Drying.
    Oyama S; Ogawa N; Kawai K; Iwai K; Yasunaga T; Yamamoto H
    Chem Pharm Bull (Tokyo); 2024; 72(2):190-199. PubMed ID: 38369345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of amorphization methods on the apparent solubility and dissolution rate of tadalafil.
    Wlodarski K; Sawicki W; Paluch KJ; Tajber L; Grembecka M; Hawelek L; Wojnarowska Z; Grzybowska K; Talik E; Paluch M
    Eur J Pharm Sci; 2014 Oct; 62():132-40. PubMed ID: 24907679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indomethacin co-amorphous drug-drug systems with improved solubility, supersaturation, dissolution rate and physical stability.
    Fael H; Demirel AL
    Int J Pharm; 2021 May; 600():120448. PubMed ID: 33675920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of the amorphous fraction of olanzapine incorporated in a co-amorphous formulation.
    da Costa NF; Fernandes AI; Pinto JF
    Int J Pharm; 2020 Oct; 588():119716. PubMed ID: 32758593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced oral bioavailability of novel mucoadhesive pellets containing valsartan prepared by a dry powder-coating technique.
    Cao QR; Liu Y; Xu WJ; Lee BJ; Yang M; Cui JH
    Int J Pharm; 2012 Sep; 434(1-2):325-33. PubMed ID: 22688251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solventless amorphization and pelletization using a high shear granulator. Part I; feasibility study using indomethacin.
    Kondo K; Rades T
    Eur J Pharm Biopharm; 2022 Dec; 181():147-158. PubMed ID: 36400256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of lipid aspirin sustained-release pellets by solvent-free extrusion/spheronization and an investigation of their stability.
    Yan X; He H; Meng J; Zhang C; Hong M; Tang X
    Drug Dev Ind Pharm; 2012 Oct; 38(10):1221-9. PubMed ID: 22713120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.